Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Antiretrovirals; HIV protease inhibitors; Raltegravir
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms BRAVO
Most Recent Events
- 02 Jul 2017 Biomarkers information updated
- 26 Jun 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 26 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.